Franklin Resources’s Allogene Therapeutics ALLO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$575K Buy
+483,157
New +$919K ﹤0.01% 2514
2023
Q4
– Sell
-24,853
Closed -$78.8K – 2640
2023
Q3
$78.8K Buy
24,853
+1,277
+5% +$5.6K ﹤0.01% 2483
2023
Q2
$117K Buy
+23,576
New +$128K ﹤0.01% 2513
2020
Q1
– Sell
-610,697
Closed -$15.9M – 1478
2019
Q4
$15.9M Sell
610,697
-178,082
-23% -$4.9M 0.01% 810
2019
Q3
$21.5M Hold
788,779
– – 0.01% 728
2019
Q2
$21.2M Sell
788,779
-200
-0% -$5.57K 0.01% 732
2019
Q1
$22.6M Buy
788,979
+289,797
+58% +$8.41M 0.01% 714
2018
Q4
$13.4M Buy
+499,182
New +$13.3M 0.01% 814

Other funds holding ALLO

Franklin Resources's ALLO Position: Q3 2026 in Review

Franklin Resources opened a new position in Allogene Therapeutics (ALLO) in Q3 2026: 483,157 shares worth $575K. The stake represents ﹤0.01% of the portfolio and ranks #2514 among its holdings. This is a return to the name: Franklin Resources previously reported a position in ALLO as recently as Q3 2023.

Franklin Resources first reported a position in ALLO in Q4 2018 and has held it in 8 quarters since. The position peaked at $22.6M in Q1 2019. 197 funds tracked by Wall St. Rank hold ALLO as of Q3 2026.

  • Franklin Resources held 483,157 shares of Allogene Therapeutics worth $575K as of Q3 2026.
  • Allogene Therapeutics was a new Franklin Resources position in Q3 2026.
  • Allogene Therapeutics made up ﹤0.01% of Franklin Resources's portfolio in Q3 2026, its #2514 holding.
  • Franklin Resources first reported a position in Allogene Therapeutics in Q4 2018 and has held it in 8 quarters since.
  • Franklin Resources's Allogene Therapeutics position peaked at $22.6M in Q1 2019.
  • 197 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q3 2026.

Based on Franklin Resources's 13F filing for Q3 2026, filed 12 Nov 2026.